Partner Content Partner Content BioPharmaLogic, Antikor Biopharma and UCL Host Two Workshops... SMi's 6th annual ADC Conference
Partner Content Partner Content Hear from Janssen and Antikor Biopharma at SMi’s ADC Confere... Janssen and Antikor Biopharma Speak this April
News Chiesi signs $1.9bn deal to buy KalVista and its HAE drug Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
